Reference health
Heart failure drug treatment: the fantastic four
13/13 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 13 checked references that resolve
resolves10.1002/ejhf.592
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
resolves10.1002/ejhf.1234
Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-Analysis
resolves10.1056/NEJMoa1911303
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
resolves10.1016/j.jchf.2020.04.008
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
resolves10.1093/eurheartj/ehaa968
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
resolves10.1016/S0140-6736(20)31824-9
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
resolves10.1016/S0140-6736(20)30748-0
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
resolves10.1093/eurheartj/ehaa183
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
resolves10.1002/ejhf.1531
Clinical Practice Update on Heart Failure 2019: Pharmacotherapy, Procedures, Devices and Patient Management. An Expert Consensus Meeting Report of the Heart Failure Association of the European Society of Cardiology
resolves10.1093/eurheartj/ehaa731
Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
resolves10.1001/jamacardio.2020.0898
Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure
The 3 references without a DOI — listed, not checked
no DOI — not checkedThe treatment of heart failure with reduced ejection fraction
no DOI — not checkedHeart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure (an update on the sodium–glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)
no DOI — not checkedSOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1093/eurheartj/ehaa1012"><img src="https://citestamp.com/citestamped/10.1093/eurheartj/ehaa1012/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1093/eurheartj/ehaa1012)